BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Market Opportunity
FLOW Logo
FLOW Price(FLOW)
$0.1757
$0.1757$0.1757
-2.17%
USD
FLOW (FLOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Buterin pushes Layer 2 interoperability as cornerstone of Ethereum’s future

Buterin pushes Layer 2 interoperability as cornerstone of Ethereum’s future

Ethereum founder, Vitalik Buterin, has unveiled new goals for the Ethereum blockchain today at the Japan Developer Conference. The plan lays out short-term, mid-term, and long-term goals touching on L2 interoperability and faster responsiveness among others. In terms of technology, he said again that he is sure that Layer 2 options are the best way […]
Share
Cryptopolitan2025/09/18 01:15
Trump rethinks China tech curbs amid Nvidia H200 review

Trump rethinks China tech curbs amid Nvidia H200 review

Trump administration has started reviewing license applications to ship Nvidia's H200 AI chips to China with a 25% fee.
Share
Cryptopolitan2025/12/19 15:41
Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

The post Polygon Tops RWA Rankings With $1.1B in Tokenized Assets appeared on BitcoinEthereumNews.com. Key Notes A new report from Dune and RWA.xyz highlights Polygon’s role in the growing RWA sector. Polygon PoS currently holds $1.13 billion in RWA Total Value Locked (TVL) across 269 assets. The network holds a 62% market share of tokenized global bonds, driven by European money market funds. The Polygon POL $0.25 24h volatility: 1.4% Market cap: $2.64 B Vol. 24h: $106.17 M network is securing a significant position in the rapidly growing tokenization space, now holding over $1.13 billion in total value locked (TVL) from Real World Assets (RWAs). This development comes as the network continues to evolve, recently deploying its major “Rio” upgrade on the Amoy testnet to enhance future scaling capabilities. This information comes from a new joint report on the state of the RWA market published on Sept. 17 by blockchain analytics firm Dune and data platform RWA.xyz. The focus on RWAs is intensifying across the industry, coinciding with events like the ongoing Real-World Asset Summit in New York. Sandeep Nailwal, CEO of the Polygon Foundation, highlighted the findings via a post on X, noting that the TVL is spread across 269 assets and 2,900 holders on the Polygon PoS chain. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 Key Trends From the 2025 RWA Report The joint publication, titled “RWA REPORT 2025,” offers a comprehensive look into the tokenized asset landscape, which it states has grown 224% since the start of 2024. The report identifies several key trends driving this expansion. According to…
Share
BitcoinEthereumNews2025/09/18 00:40